Chardan analyst Keay Nakae raised the firm’s price target on Alnylam (ALNY) to $475 from $400 and keeps a Buy rating on the shares following the Q3 report. The company’s early sales trajectory of Amvuttra for ATTR-CM is “impressive,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam Pharmaceuticals Reports Strong Q3 2025 Growth
- Alnylam Pharma’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating
- Alnylam Pharma’s Strong Q3 Performance and Promising Outlook Reinforce Buy Rating Despite Legal Concerns
- Alnylam price target raised to $495 from $475 at Morgan Stanley
- Alnylam price target lowered to $549 from $550 at Jefferies